Pacira BioSciences, Inc.PCRXNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

25 analysts·High coverage

56%

Rating Distribution

Strong Buy

00%

Buy

1456%

Hold

936%

Sell

28%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 27% higher.

Bear Case

$27.00

+27%

Consensus

$27.00

+27%

Bull Case

$27.00

+27%

Price Range25 analysts

Low

Consensus

High

$27.00

Current Target

Current Price

$21.22

Upside to Target

$5.78

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$3.41(4 analysts)

P/E44x

Current: 43.6x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+9.06%

EPS+12.91%

FY2028

Rev+5.40%

EPS+5.78%

FY2029

Rev+2.42%

EPS+12.53%

Earnings Surprises

Beat rate:50%(6/12 quarters)

Avg surprise:+2.9%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Dec 8, 2025Barclays

Pacira initiated with an Equal Weight at Barclays

Target:$27.00

+10.6%from $24.42

Feb 28, 2025Barclays

Pacira price target raised to $24 from $17 at Barclays

Target:$24.00

-0.2%from $24.05

Feb 28, 2025H.C. Wainwright

Pacira price target raised to $48 from $39 at H.C. Wainwright

Target:$48.00

+99.6%from $24.05

Jan 30, 2025Truist Financial

Truist Securities Upgrades Pacira Pharmaceuticals (PCRX) to Buy

Target:$25.00

-4.0%from $26.03

Nov 7, 2024Piper Sandler

Pacira Pharmaceuticals (PCRX) PT Raised to $12 at Piper Sandler

Target:$12.00

-30.9%from $17.36

Sep 24, 2024Jefferies

Pacira Pharmaceuticals (PCRX) PT Raised to $18 at Jefferies

Target:$18.00

+21.9%from $14.77

Aug 13, 2024Truist Financial

Pacira downgraded to Sell from Buy at Truist

Target:$8.00

-34.9%from $12.29

Jul 2, 2024H.C. Wainwright

Pacira should be bought on today's selloff, says H.C. Wainwright

Target:$57.00

+160.2%from $21.91

Jun 13, 2024Jefferies

Jefferies Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX)

Target:$36.00

+26.3%from $28.50

May 21, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Pacira Pharmaceuticals (PCRX)

Target:$42.00

+36.9%from $30.68

Jan 6, 2023BMO Capital

BMO Capital Maintains Market Perform on Pacira BioSciences, Lowers Price Target to $52

Target:$52.00

+35.1%from $38.50

Jan 6, 2023Needham

Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $63

Target:$63.00

+63.6%from $38.50

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance